Study

A recent study published in the “Lancet” Medical Journal “Simajlotide” anti -obviousity, commercially known as “Ozmbek”, contains cardiovascular benefits for people suffering from heart failure. The palaces of the heart are a significant weakness in the ability of the muscle to pump blood into the body. Previous studies of the same team conducted by the current study said that the medicine could prevent “simaglotide” heart attacks, and other major heart attacks between people associated with weight gain associated with cardiovascular disease. The lead author of the study, John Denfield, a professor at the Cardiovascular Institute at the University of London, said the previous analysis the existence of the benefits of the drug for people with weight gain and cardiovascular diseases, “but concerns about the possibility of damage to people with a kind of heart failure.” Denfeld added that the benefit of the middle was the same, regardless of the kind of heart failure, and explained: “This new study finds that the performance of people with heart failure in this group was good as people who are not infected with the results we completed.” The researchers followed the tests of 4 and 286 people for 3 years, from a total of 17 thousand and 605 people from the ‘Celtic’ experience, which is the largest and longest clinical experience involved in studying the effect of using the medicine on cardiovascular health. The researchers found that ‘Simaglotide’ is linked to a 28% decline in the most important cordial events, in addition to a 24% decline in deaths associated with cardiovascular disease of this subgroup of people, suffering from a pre -heart failure, and a 19% decrease in death. Improving weight loss and the acquisition of simajlotide, originally developed as a treatment for type 2 diabetes, is a great interest in its effectiveness in weight loss. The drug works as a stimulant for peptide-1 peptide-like receptors (GLP-1), which not only helps regulate blood sugar levels, but also limits the appetite, leading to a significant decline in weight. However, recent research has shown that the benefits of Simajlotide extend to weight loss and glucose control. Simaglotide is also the active component of the ‘Ozmbek’ and ‘Wigofi’ drug, and in July, thanks to the evidence from the ‘Celtic’ experience, the British medicine regulatory authority agreed to have ‘wigofi’ as a treatment for those suffering from cardiovascular disease, which means it can be prescribed. The microscopic mechanism in which the drug simaglotide works on the provision of unknown cardiovascular benefits, but this may include the positive effects of the drug on blood sugar, blood pressure and infections, as well as direct effects on cardiovascular muscle. The researchers said that the decline in the death rate of all causes in all heart failure groups “indicates the possibility of bringing about other benefits that are not yet known.” The study compared the effect of simajlotide on people with two types of heart failure; These are the palaces of the shell fracture, because the heart pumps the blood naturally, but it is very stiff so that it is not properly filled, and the rupture with a low garden. These two types of heart failure have different causes and their response to treatment is different, as maintaining the shell fracture, which is the most common, does not respond well to traditional treatments, leading to a large clinical need that has not been resolved. Medical benefits, and the researchers found that the clinical advantage of simaglotide was great, regardless of the kind of heart failure. They also found it independent of age and gender, the basic body mass index and clinical condition. Dangerous negative events were reported more frequently in the fictional drug group compared to the Simajlotide group. The researchers said that these results support the use of symbolotide, in addition to ordinary care, to reduce the risk of major negative heart events at a wide range of people with cardiovascular disease, negligence and weight gain or obesity. The researchers noted that more experiments are needed to determine the effect of simblotide on the results associated with heart failure. They said that the results of the study cannot be withdrawn on patients who generally suffer from heart failure because the ‘Celtic’ experience was not an experience dedicated to heart failure. The researchers believe that the capabilities of simjlotide in reducing the occurrence of severe heart and blood vessels in different groups of patients are great progress in cardiovascular care. As the global burden of heart disease continues, medications that can treat several risk factors at the same time are invaluable. The researchers say that the double work of simjlotide as a weight loss factor and a protector of the heart and blood vessels can lead to more specialized and effective therapeutic strategies for the population at risk.